| Variables . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Radiology | |||
| Lesion enhancement | 6 (54.5) | 16 (36.3) | NS |
| Bone absorptions or destructions | 3 (27.2) | 11 (25.0) | NS |
| Orbital or optic nerve abnormalities | 3 (27.2) | 13 (29.5) | NS |
| CNS radiological abnormalities | 5 (45.4) | 19 (43.2) | NS |
| Involvement sites | |||
| Paranasal sinus | |||
| Single sinus | 2 (18.1) | 12 (27.3) | NS |
| Multi sinus | 9 (81.8) | 33 (75) | NS |
| Frontal sinus | 3 (27.3) | 12 (27.3) | NS |
| Sphenoid sinus | 6 (54.5) | 30 (68.2) | NS |
| Ethmoid sinus | 9 (81.8) | 27 (61.4) | NS |
| Maxillary sinus | 8 (72.7) | 31 (70.5) | NS |
| Ocular involvement | 5 (45.5) | 22 (50.0) | NS |
| CNS involvement | 5 (45.5) | 20 (45.5) | NS |
| Ocular and CNS involvement | 3 (27.3) | 7 (15.9) | NS |
| Other sites | |||
| Mastoid process | 2 (18.1) | 3 (6.8) | NS |
| Lung | 1 (9.1) | 5 (11.4) | NS |
| Facial region | 0 (0) | 3 (6.8) | NS |
| Etiology | |||
| Aspergillus spp. | 9 (81.8) | 40 (90.9) | |
| Aspergillus fumigates | 1 (9.1) | 1 (2.3) | NS |
| Candidal albicans | 0 (0.0) | 1 (2.3) | NS |
| Zygomycete | 0 (0.0) | 3 (6.8) | NS |
| Dematiaceous hyphomycetes | 1 (9.1) | 0 (0.0) | NS |
| Death | 0 (0.0) | 6 (13.6) | NS |
| Symptom onset to diagnosis | |||
| Median time, mo | 4 | 24 | .001 |
| Variables . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Radiology | |||
| Lesion enhancement | 6 (54.5) | 16 (36.3) | NS |
| Bone absorptions or destructions | 3 (27.2) | 11 (25.0) | NS |
| Orbital or optic nerve abnormalities | 3 (27.2) | 13 (29.5) | NS |
| CNS radiological abnormalities | 5 (45.4) | 19 (43.2) | NS |
| Involvement sites | |||
| Paranasal sinus | |||
| Single sinus | 2 (18.1) | 12 (27.3) | NS |
| Multi sinus | 9 (81.8) | 33 (75) | NS |
| Frontal sinus | 3 (27.3) | 12 (27.3) | NS |
| Sphenoid sinus | 6 (54.5) | 30 (68.2) | NS |
| Ethmoid sinus | 9 (81.8) | 27 (61.4) | NS |
| Maxillary sinus | 8 (72.7) | 31 (70.5) | NS |
| Ocular involvement | 5 (45.5) | 22 (50.0) | NS |
| CNS involvement | 5 (45.5) | 20 (45.5) | NS |
| Ocular and CNS involvement | 3 (27.3) | 7 (15.9) | NS |
| Other sites | |||
| Mastoid process | 2 (18.1) | 3 (6.8) | NS |
| Lung | 1 (9.1) | 5 (11.4) | NS |
| Facial region | 0 (0) | 3 (6.8) | NS |
| Etiology | |||
| Aspergillus spp. | 9 (81.8) | 40 (90.9) | |
| Aspergillus fumigates | 1 (9.1) | 1 (2.3) | NS |
| Candidal albicans | 0 (0.0) | 1 (2.3) | NS |
| Zygomycete | 0 (0.0) | 3 (6.8) | NS |
| Dematiaceous hyphomycetes | 1 (9.1) | 0 (0.0) | NS |
| Death | 0 (0.0) | 6 (13.6) | NS |
| Symptom onset to diagnosis | |||
| Median time, mo | 4 | 24 | .001 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CIFRS, chronic invasive fungal rhinosinusitis; CNS, central nervous system; GIFRS, granulomatous invasive fungal rhinosinusitis; NS, no significance.
| Variables . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Radiology | |||
| Lesion enhancement | 6 (54.5) | 16 (36.3) | NS |
| Bone absorptions or destructions | 3 (27.2) | 11 (25.0) | NS |
| Orbital or optic nerve abnormalities | 3 (27.2) | 13 (29.5) | NS |
| CNS radiological abnormalities | 5 (45.4) | 19 (43.2) | NS |
| Involvement sites | |||
| Paranasal sinus | |||
| Single sinus | 2 (18.1) | 12 (27.3) | NS |
| Multi sinus | 9 (81.8) | 33 (75) | NS |
| Frontal sinus | 3 (27.3) | 12 (27.3) | NS |
| Sphenoid sinus | 6 (54.5) | 30 (68.2) | NS |
| Ethmoid sinus | 9 (81.8) | 27 (61.4) | NS |
| Maxillary sinus | 8 (72.7) | 31 (70.5) | NS |
| Ocular involvement | 5 (45.5) | 22 (50.0) | NS |
| CNS involvement | 5 (45.5) | 20 (45.5) | NS |
| Ocular and CNS involvement | 3 (27.3) | 7 (15.9) | NS |
| Other sites | |||
| Mastoid process | 2 (18.1) | 3 (6.8) | NS |
| Lung | 1 (9.1) | 5 (11.4) | NS |
| Facial region | 0 (0) | 3 (6.8) | NS |
| Etiology | |||
| Aspergillus spp. | 9 (81.8) | 40 (90.9) | |
| Aspergillus fumigates | 1 (9.1) | 1 (2.3) | NS |
| Candidal albicans | 0 (0.0) | 1 (2.3) | NS |
| Zygomycete | 0 (0.0) | 3 (6.8) | NS |
| Dematiaceous hyphomycetes | 1 (9.1) | 0 (0.0) | NS |
| Death | 0 (0.0) | 6 (13.6) | NS |
| Symptom onset to diagnosis | |||
| Median time, mo | 4 | 24 | .001 |
| Variables . | Patients With GIFRS (n = 11) . | Patients With CIFRS (n = 44) . | P Value . |
|---|---|---|---|
| Radiology | |||
| Lesion enhancement | 6 (54.5) | 16 (36.3) | NS |
| Bone absorptions or destructions | 3 (27.2) | 11 (25.0) | NS |
| Orbital or optic nerve abnormalities | 3 (27.2) | 13 (29.5) | NS |
| CNS radiological abnormalities | 5 (45.4) | 19 (43.2) | NS |
| Involvement sites | |||
| Paranasal sinus | |||
| Single sinus | 2 (18.1) | 12 (27.3) | NS |
| Multi sinus | 9 (81.8) | 33 (75) | NS |
| Frontal sinus | 3 (27.3) | 12 (27.3) | NS |
| Sphenoid sinus | 6 (54.5) | 30 (68.2) | NS |
| Ethmoid sinus | 9 (81.8) | 27 (61.4) | NS |
| Maxillary sinus | 8 (72.7) | 31 (70.5) | NS |
| Ocular involvement | 5 (45.5) | 22 (50.0) | NS |
| CNS involvement | 5 (45.5) | 20 (45.5) | NS |
| Ocular and CNS involvement | 3 (27.3) | 7 (15.9) | NS |
| Other sites | |||
| Mastoid process | 2 (18.1) | 3 (6.8) | NS |
| Lung | 1 (9.1) | 5 (11.4) | NS |
| Facial region | 0 (0) | 3 (6.8) | NS |
| Etiology | |||
| Aspergillus spp. | 9 (81.8) | 40 (90.9) | |
| Aspergillus fumigates | 1 (9.1) | 1 (2.3) | NS |
| Candidal albicans | 0 (0.0) | 1 (2.3) | NS |
| Zygomycete | 0 (0.0) | 3 (6.8) | NS |
| Dematiaceous hyphomycetes | 1 (9.1) | 0 (0.0) | NS |
| Death | 0 (0.0) | 6 (13.6) | NS |
| Symptom onset to diagnosis | |||
| Median time, mo | 4 | 24 | .001 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CIFRS, chronic invasive fungal rhinosinusitis; CNS, central nervous system; GIFRS, granulomatous invasive fungal rhinosinusitis; NS, no significance.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
